Carolyn Matthews, MD
Gynecologic Oncology · Manassas, VANPI 1649213158
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,800 of the $3,718 with a category attached, or 75.3%. AstraZeneca accounts for 76.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $2,859 and has fallen 97.1% since, to $83 in 2023.
Across 16 payments — averaging $232.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Myriad Genetic Laboratories, Inc.$506
- Heron Therapeutics, Inc.$161
- Genmab U.S., Inc.$109
- KARL Storz Endoscopy-america$53
- Coopersurgical, Inc.$17
- plus $16 from 2 others
Across 4 payments — averaging $36,019 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$134K
- Karyopharm Therapeutics Inc.$10K
What the payments were for
- Consulting fees$2,80075%
- Food & beverage$90224%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $2,856 |
| Myriad Genetic Laboratories, Inc. | 5 | $506 |
| Heron Therapeutics, Inc. | 1 | $161 |
| Genmab U.S., Inc. | 1 | $109 |
| KARL Storz Endoscopy-america | 2 | $53 |
| Coopersurgical, Inc. | 1 | $17 |
| Intuitive Surgical | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$2,800
- myChoice CDx$242
- PreciseTumor$224
- SUSTOL$161
- TIVDAK$109
How this compares
$3,718 in reported general payments places this provider in the 65th percentile of 47 gynecologic oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tramadol Hcl | 19 | $32 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Manassas
- Cecelia BoardmanRichmond$577K
- Leslie RandallFairfax$342K
- Chad HamiltonAnnandale$242K
- Samantha BatmanCharlottesville$76K
- Linda DuskaCharlottesville$72K
- Marilyn HuangCharlottesville$39K
- Kari RingCharlottesville$14K
- Randal WestRichmond$8K
- John ElkasFairfax$7K
- Annette BicherAnnandale$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.